Anuh Pharma reports a 5% year-on-year increase in Q4 revenue, reaching INR 2 billion compared to the previous year's INR 1.9 billion.

Anuh Pharma announces a net profit of INR 41.05 crore for FY26, coupled with a dividend of INR 1.50 per share. Additionally, two directors have been reappointed, a new General Manager has been appointed, and updated Memorandum and Articles of Association (MOA/AOA) have been adopted.

Anuh Pharma secures WHO approval for Amodiaquine Hydrochloride USP, enhancing their contribution to the global market of anti-malarial active pharmaceutical ingredients. This recognition also positions them favorably for participation in donor-funded programs.